Satellos Completes BASECAMP Phase 2 Enrollment, Delays Topline Data to Q1 2027
MSLE sits 58% above its 52-week low of $5.44 on elevated volume (7.6× avg).
Summary
Satellos completed enrollment in its BASECAMP Phase 2 DMD trial ahead of schedule but delayed topline data to Q1 2027 to build a more complete dataset for potential FDA accelerated approval discussions.
Key Events · Product Development and Regulatory · MSLE
-
BASECAMP Enrollment Completed
Enrollment surpassed target in under nine months across 18 sites in the U.S., Canada, Australia, Belgium, Spain, Poland, and Serbia.
-
Topline Data Delayed to Q1 2027
Company adjusted its prior data-release plan, now targeting Q1 2027 to compile the most complete dataset for potential FDA accelerated approval discussions.
-
Trial Design Details
Participants randomized 1:1:1 to forazapadin 60 mg, 120 mg, or placebo; 12-week placebo-controlled period followed by 36-week active treatment.
-
Accelerated Pathway Ambition
Management believes BASECAMP could support FDA discussions on an accelerated development pathway for forazapadin in DMD.
Analysis · MSLE · Life Sciences
Satellos finished enrolling its pivotal BASECAMP Phase 2 trial for forazapadin in Duchenne muscular dystrophy, exceeding its target in under nine months. The company also pushed topline data from a previously implied earlier timeline to Q1 2027, citing a desire to compile the most complete dataset for potential FDA accelerated approval discussions. The delay is a modest negative — investors now wait longer for the key readout — but the rapid enrollment and explicit accelerated-pathway language keep the overall story constructive.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MSLE was trading at $8.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $182.5M. The 52-week trading range was $5.44 to $144.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.